The $250B Licensing Surge: How to Value Deals in a Record...
As biopharma licensing volumes reach unprecedented levels, disciplined valuation has never been more critical The biopharma licensing...
The “Makary Doctrine” and the Billion-Dollar Impact of the Single-Trial Default
In December 2025, FDA Commissioner Dr. Marty Makary announced a policy shift that biopharma consultants have termed...
The $3.2 Billion Follow-on Signal: What this means for the 2026...
After lacklustre years the biotech markets have been waiting for a positive indicative signal, and we likely...
Tokenization in Biopharma Licensing
How Tokenization can Transform Pharma Licensing and Royalty Financing The pharmaceutical and biotech industries face a critical...
The Rise of Synthetic Royalties and Royalty-Backed Debt in Europe
European Growth and Market Dynamics Royalty financing and synthetic royalties are reshaping biotech and pharma funding in...
CAR-T Cell Therapy: Evolution, Adoption, and the Road Ahead
As a life sciences focused valuation and advisory firm, we observe the transformative potential of Chimeric Antigen...
From Lab to Liquidity: Royalty and Milestone Monetization for Universities and...
From Lab to Liquidity: Royalty and Milestone Monetization for Universities and Inventors Universities, research institutes, and academic...
Step into the Future of Informed Decision-Making: How RIVAL Software Empowers...
Step into the Future of Informed Decision-Making: How RIVAL Software Empowers Pharma and Biotech In the high-stakes...
Understanding Synthetic Royalties: A Creative Twist on Drug Monetization
In the high-stakes world of pharmaceuticals, turning a promising molecule into a marketed drug is a marathon...
The Influence of Taxes on Deals in the Biotech and Pharma...
The Influence of Taxes on Deals in the Biotech and Pharma Industry: A Strategic Perspective for Optimizing...